Bacopa Monnieri for ADHD

Verdict: Weak, disputed evidence for ADHD

Bacopa monnieri has only weak and conflicting evidence for childhood ADHD: a handful of small trials hint at modest benefit, but the best-designed study missed its main behavioral outcome, and specialty bodies say there is not enough evidence that it reduces ADHD symptoms.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade rests on a thin, mostly small-trial base. The strongest study, a 2022 double-blind RCT in 93 boys aged 6 to 14 (PMID 35041248), found no significant difference on its primary behavioral outcome; benefits appeared only on secondary cognitive, executive-function and sleep measures, and the trial was funded by a supplement manufacturer. A 2016 systematic review (PMID 27912958) pooled five pediatric studies and reported a small-to-medium effect (mean d=0.42) on hyperactivity and attention, but its authors explicitly called for more rigorous replication.

The remaining support is weaker still. A 2014 open-label study (PMID 24682000) reported broad symptom improvement but had no control group and only 31 children. A 2022 systematic review and meta-analysis of herbal ADHD treatments (PMID 35592415) listed bacopa among herbs with a 'fair indication' of efficacy and safety, yet concluded there was inadequate proof to strongly recommend herbal therapy for ADHD.

Expert guidance reinforces the cautious verdict. CHADD names bacopa among complementary products and states plainly that 'there is not enough evidence that these herbs and supplements decrease ADHD symptoms.' US regulators treat it only as a dietary supplement, and major clinical references (Mayo Clinic, Cleveland Clinic, Harvard Health, NIH ODS, NHS, EFSA, WHO) offer no specific endorsement for ADHD. Together this yields genuinely mixed, weak evidence rather than a clear positive signal.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.54
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
77%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.38
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.537
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effects of Bacopa monnieri (CDRI 08) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: A randomized, double-blind, placebo-controlled trial
PMID: 35041248 2022 RCT (double-blind) n = 93
Finding: No significant behavioral group differences; CDRI 08 favored on decreased error-making (p=.04), cognitive flexibility (p=.01), executive functioning (p=.04), interpersonal problems (p=.02) and sleep routine (p=.04).
⚠️ Industry-funded
View on PubMed
A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations
PMID: 27912958 2016 系統性回顧
Finding: Five studies; significant improvements in hyperactivity and attention-deficit domains, with overall small-to-medium effect (mean d=0.42); authors call for more rigorous replication.
Effect size: [object Object]
View on PubMed
An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children
PMID: 24682000 2014 RCT (open-label) n = 31
Finding: Restlessness reduced in 93%, self-control improved in 89%, attention-deficit reduced in 85%; 74% had up to 20% reduction and 26% had 21-50% reduction in total symptom score.
🟠 Limited quality
View on PubMed
Phytotherapy for Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review and Meta-analysis
PMID: 35592415 2022 統合分析
Finding: Seven RCTs in children/adolescents; Bacopa monnieri among herbs with fair indication of efficacy/safety, but overall inadequate proof to strongly recommend herbal therapy for ADHD.
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
L5e Specialty Society (condition-mapped)
Against
There is not enough evidence that these herbs and supplements decrease ADHD symptoms, however. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-adhd-INT-bacopa-monnieri-001 繁體中文版 →